European regulators say Yes to GE's purchase of Amersham

The European Union (EU) on Wednesday gave its blessing to General Electric Co.'s (GE) proposed $9.5 billion acquisition of Amersham plc.

The transaction would catapult GE Medical Systems (GEMS) into the pharmaceutical market, particularly in the segment of contrast imaging agents.

EU regulators determined that the "bundling" of Amersham's contrast imaging agents and GEMS' medical imaging technology was not a serious issue, in that "neither GE nor Amersham hold dominant positions in their respective products in Europe."

The EU added that GEMS' competitors - from other medical imaging technology companies, such as Siemens Medical Solutions, Philips Medical Systems International and Toshiba Corp. - will remain strong competition in the wake of the GE-Amersham acquisition. Amersham's primary competition in pharmaceuticals comes from Schering AG and Bristol-Myers Squibb Co.

GE and Amersham plan to complete the acquisition in April.

If and when the transaction is approved, Amersham would be GE's second major transaction in Europe in six months. The company completed its acquisition of Instrumentarium Corp., of Helsinki, in October 2003 for approximately $2.1 billion.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.